This New Peptide Could Help Millions of People Replace Insulin Injections with Daily Pills

For now, the treatment works in mice.

For millions of people living with diabetes, an insulin pill is kind of like a flying car: always around the corner, never actually delivered. The problem isn’t the insulin itself; it’s the human body. Our digestive tracts are incredibly efficient at shredding proteins, and insulin (a fragile protein) rarely survives the trip to the bloodstream.

But researchers at Kumamoto University might have finally found the right bodyguard for the job. The work is still early, but it points to a simpler and more efficient approach than many earlier attempts.

A Hostile Trip Through the Gut

The stomach is a hostile environment. If the stomach’s acids somehow don’t destroy the insulin, the intestinal enzymes certainly will. Even if a few molecules survive that gauntlet, they hit a second wall: the intestinal lining. This lining is built to keep large molecules out, and insulin is a bulky guest.

The Kumamoto team, led by Associate Professor Shingo Ito, took aim at the second problem with what it calls a DNP peptide—a cyclic peptide able to cross the small intestine. Instead of treating the gut as an impenetrable wall, the researchers tried to exploit a route through it.

They tested two versions of the idea.

In one, they mixed a modified peptide called D-DNP-V with insulin hexamers—clusters of insulin molecules held in a more durable form. In the other, they chemically linked the peptide directly to insulin using click chemistry, a method that lets scientists snap molecules together with high precision.

Both approaches worked in mice.

Two Paths, One Result

The former approach may be the more promising of the two. The peptide temporarily associates with the insulin complex and appears to promote transport across the intestinal lining. That spares researchers from having to chemically alter every insulin molecule.

×

Get smarter every day...

Stay ahead with ZME Science and subscribe.

Daily Newsletter
The science you need to know, every weekday.

Weekly Newsletter
A week in science, all in one place. Sends every Sunday.
No spam, ever. Unsubscribe anytime. Review our Privacy Policy.

Thank you! One more thing...

Please check your inbox and confirm your subscription.

In both cases, the animals’ blood sugar fell sharply after oral dosing. The researchers report that once-daily treatment maintained glucose control for three consecutive days in the mouse experiments.

Part of the appeal is that the method appears less complicated than many earlier attempts. Other oral-insulin designs have often depended on intricate carriers or layered protective systems. Here, the researchers used a more direct formulation that acted quickly in mice and delivered insulin with relatively strong efficiency.

“Insulin injections remain a daily burden for many patients,” said Shingo Ito, an associate professor at Kumamoto University who led the study. “Our peptide-based platform offers a new route to deliver insulin orally and may be applicable to long-acting insulin formulations and other injectable biologics.”

But getting the right dose is also a challenge.

Dose Matters

Many past efforts have needed more than ten times the injected dose to produce a meaningful effect. That creates practical problems fast. Large doses raise costs, which complicates manufacturing and can make drug levels harder to control.

The new platform achieved about 33–41% pharmacological bioavailability relative to subcutaneous injection in mice. In plain terms, a substantial fraction of the swallowed insulin seems to have produced an effect similar to injected insulin, rather than being destroyed or lost on the way. We’re getting close to a comparable level of treatment.

The researchers also found that the system depended on careful fine-tuning. The balance between the peptide and insulin affected how well blood sugar fell, while zinc helped protect insulin from being broken down in the intestine before it could be absorbed.

The team then tested the same approach with longer-acting insulin analogs, including detemir and degludec. In mice, those versions also produced sustained blood-sugar-lowering effects, suggesting the method may work not only with standard insulin but with longer-lasting formulations as well.

RelatedPosts

Drinking Sugar May Be Far Worse for You Than Eating It, Scientists Say
Scientists come mighty close to delivering insulin in a pill
Sea Snails Paralyze Their Prey With Unique Type of Insulin
Just Five Days of Junk Food Can Throw Off Your Brain’s Metabolism

Promise, With the Usual Cautions

For all its promise, the work remains an animal study. Mice intestines differ from ours, and many drug-delivery ideas that succeed in rodents stumble later in larger animals or in people.

The researchers are already moving to the next stage, with plans to test the approach in larger animals and in systems that mimic the human intestine. An oral insulin pill must deliver a reliable dose despite the chaos of daily life—meals, stomach acidity, intestinal motion, other medications, and the wide variation from one patient to another.

Even at this early stage, the findings give researchers something firmer to build on. Instead of simply showing that oral insulin might be possible, the study identifies a workable transport strategy that performed well in mice.

The study was published in the journal Molecular Pharmaceutics.